Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Hormes

Neuromusculoskeletal Medicine & OMM Marietta, GA Medical Doctor

NPI 1497848444 CMS profile 158016

780 Canton Road Ne, Suite 400, Marietta, GA 30060

Open in the dashboard

General payments

$5,533

317 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Hormes of Marietta, GA is reported in the CMS Open Payments database as having received $5,533 across 317 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neuromusculoskeletal Medicine & OMM profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $214 6
2024 General $222 9
2023 General $544 25
2022 General $229 11
2021 General $493 38
2020 General $727 50
2019 General $3,106 178

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Hormes
  • Neuromusculoskeletal Medicine & OMM median
  • Middle half of Neuromusculoskeletal Medicine & OMM
  • National median

In program year 2025, general payments to Joseph Hormes were reported at $214. Among 217 Neuromusculoskeletal Medicine & OMM profiles paid that year, the median was $119 and the middle half received between $36 and $380.

Show as a table
Year Joseph Hormes Neuromusculoskeletal Medicine & OMM median Middle half National median
2019 $3,106 $92 $27–$283 $163
2020 $727 $85 $20–$411 $114
2021 $493 $120 $32–$548 $132
2022 $229 $96 $32–$518 $149
2023 $544 $92 $33–$328 $160
2024 $222 $122 $35–$378 $164
2025 $214 $119 $36–$380 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $587 37 payments
  2. ACADIA Pharmaceuticals Inc $403 20 payments
  3. Allergan Inc. $392 33 payments
  4. Novartis Pharmaceuticals Corporation $378 25 payments
  5. EMD Serono, Inc. $375 22 payments
  6. Greenwich Biosciences, Inc. $347 10 payments
  7. Supernus Pharmaceuticals, Inc. $246 11 payments
  8. Genzyme Corporation $225 11 payments
  9. Ge Healthcare $222 14 payments
  10. Sunovion Pharmaceuticals Inc. $201 14 payments
  11. Other $2,156 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,388 309 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $121 6 payments
  3. Education $13 1 payment
  4. Consulting Fee $10 1 payment
Products named General payments · program years 2019–2025
  1. NUPLAZID $403 20 payments
  2. Epidiolex $347 10 payments
  3. BOTOX Hyperhydrosis $340 23 payments
  4. AIMOVIG $277 19 payments
  5. TROKENDI XR $246 11 payments
  6. APTIOM $222 15 payments
  7. UBRELVY $206 19 payments
  8. BOTOX Botox Therapeutic $187 6 payments
  9. AUBAGIO $183 9 payments
  10. Soliris $170 8 payments
  11. Other $3,347 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

41

Median for Osteopathic Manipulative Medicine: 311

Drug cost

$21,489

Median for Osteopathic Manipulative Medicine: $11,323

Branded share of claims

100%

Median for Osteopathic Manipulative Medicine: 19.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aimovig Autoinjector Erenumab-Aooe Brand 29 $21,066
Memantine Hcl Er Memantine Hcl Brand 12 $423

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 526 Part D prescribers listed as Osteopathic Manipulative Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISUNLA
  • Lilly USA, LLC $26
$26 — —
APTIOM
  • Sumitomo Pharma America, Inc. $25
$25 — —
Leqembi
  • Eisai Inc. $22
$22 — —
AMYVID
  • Lilly USA, LLC $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

317 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromusculoskeletal Medicine & OMM in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record